Consumption of garlic not associated decreased risk of colorectal cancer
the ONA take:
According to a new study published in World Journal of Gastroenterology, researchers have found that the consumption of raw or cooked garlic or garlic supplements is not significantly linked with a decreased risk for developing colorectal cancer.
For the study, researchers sought to conduct a meta-analysis of trials that prospectively studied the association between garlic or garlic supplement consumption and colorectal cancer. They identidfied five prospective studies that looked at either the consumption of garlic, whether raw or cooked, or garlic supplements and its association with the development of colorectal cancer.
Relative risks with 95% confidence intervals were calculated. Unlike a previous meta-analysis that did identify a significant association between raw or cooked garlic and cancer, this study did not. Researchers found a relative risk of 1.06 (95% CI: 0.95 - 1.19) between consumption of raw or cooked garlic and risk of colorectal cancer.
In addition, the relative risk between garlic supplements and risk of cancer was 1.12 (95% CI: 0.96 - 1.31). Researchers did find, however, non-significant protective benefit of garlic supplements against colorectal cancer in women (RR = 0.84, 95 CI: 0.64 - 1.11), but the opposite effect in men (RR = 1.24; 95% CI: 0.96 - 1.59).
Consumption of raw or cooked garlic or garlic supplements not significantly linked.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|